Navigation Links
Three Organizations Receive CEO Cancer Gold Standard(TM) Accreditation

Duke Medicine, University of North Dakota and Valeant Pharmaceuticals join

workplace wellness leadership effort

CARY, N.C., Oct. 11 /PRNewswire-USNewswire/ -- Today, three organizations, Duke Medicine, The University of North Dakota and Valeant Pharmaceuticals, were accredited with the CEO Cancer Gold Standard(TM), certifying their commitment to the health of their employees and their families by agreeing to meet an exceptionally high standard of cancer prevention, screening and care guidelines. In doing so, they join with thirteen other organizations that have answered former President George H.W. Bush's call for business leaders to be "bold and venturesome" in their efforts in preventing cancer in the workplace and in their leadership in the overall fight against cancer.

William C. Weldon, chairman and chief executive officer of Johnson & Johnson, chairs the CEO Roundtable on Cancer, the nonprofit organization of cancer-fighting CEOs that created the CEO Cancer Gold Standard(TM), in collaboration with leading health professionals. "Adopting the Gold Standard is a tribute to the value these CEOs place on their employees and to the extraordinary leadership they provide their organizations and to all of those committed to winning the battle against cancer."

The CEO Cancer Gold Standard(TM), calls for companies to evaluate their benefits and culture and take extensive, concrete actions in five key areas of health and wellness to fight cancer in the workplace. To earn Gold Standard accreditation, a company must establish programs to reduce cancer risk by discouraging tobacco use and encouraging physical activity, healthy diet and nutrition; detect cancer at its earliest stages; and provide access to quality care, including the availability of clinical trials.

Earlier this year, the President's Cancer Panel report, "Promoting Healthy Lifestyles: Policy, Program, and Personal Recommendations for Reducing Cancer Risk," identified the CEO Cancer Gold Standard(TM) as an initiative that is helping reverse negative, unhealthy lifestyle trends and creating hope in the fight against cancer for America's workers and their families.

In addition to Duke Medicine, The University of North Dakota and Valeant Pharmaceuticals, thirteen other companies have received the CEO Cancer Gold Standard(TM) accreditation from the CEO Roundtable on Cancer. They are: American Cancer Society (national headquarters), American Legacy Foundation, AstraZeneca, Edelman, Enzon Pharmaceuticals, GlaxoSmithKline, Jenner & Block, Johnson & Johnson, MD Anderson Cancer Center, Novartis, OSI Pharmaceuticals, Quintiles Transnational and SAS Institute.

About the CEO Roundtable on Cancer

The CEO Roundtable on Cancer was founded in 2001, when former President George H.W. Bush challenged a group of executives, led by Robert A. Ingram, then the CEO of Glaxo Wellcome, now GlaxoSmithKline, to "do something bold and venturesome about cancer within your own corporate families." The CEOs responded with the CEO Cancer Gold Standard, and have since collaborated with the American Cancer Society to encourage its widespread adoption in workplaces across the country. For more information on the CEO Cancer Gold Standard(TM) and the accreditation process, please call 866-526-7830 or visit

For more information:

CEO Roundtable on Cancer

John Dornan, Executive Director

P: 919-531-0966


To read the President's Cancer Panel report, please go to:

This release was issued through eReleases(TM). For more information, visit

SOURCE CEO Roundtable on Cancer
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. One in Three Heart Attack Patients Have No Chest Pains
2. Nobel Prize for Medicine shared by Three scientists
3. Biotechnology industry expected to grow into a three billion dollar industry by 2002
4. Baltimore doctors perform three simultaneous kidney transplants
5. FDA gives “black box warning” against three asthma drus
6. Three Tropical Parasites Genetic Code Unravelled
7. The Future Pattern Of Weight Gain Is Laid As Early As Three Years Of Age
8. Smoking Increases The Risk Of Heart Disease By Three Times
9. Three Sisters Have One Baby and Make History
10. Three In One Ultrasound Probe For 3-D Imaging Of Heart And Tissue Destruction Developed
11. Three More Bird Flu Cases Reported By China
Post Your Comments:
(Date:11/27/2015)... ... November 27, 2015 , ... An inventor, from Hopkinsville, ... prescription medications at home, so he invented the patent-pending ELECTRONIC M.D. , The ... medications. In doing so, it could help to prevent potential overdose situations. As ...
(Date:11/27/2015)... ... ... Lizzie’s Lice Pickers just announced a special promotion that will run throughout ... of lice treatment product. In addition, customers will receive a complimentary head Check when ... is a sure way to ruin the holidays, so we encourage all of our ...
(Date:11/27/2015)... Aliso Viejo, CA (PRWEB) , ... November 27, 2015 , ... ... exclusively for use in Final Cut Pro X. With ProSidebar: Fasion, video editors ... banners, or use ProSidebar as a minimalist title opener. Utilize presets featuring self-animating ...
(Date:11/27/2015)... ... November 27, 2015 , ... Consistent with the ... 2016 Building Better Radiology Marketing Programs meeting will showcase some of ... 6, 2016, at Caesars Palace in Las Vegas with a pre-conference session on ...
(Date:11/27/2015)... ... ... A simply groundbreaking television series, "Voices in America", which is hosted by Hollywood legend, ... that are presently affecting Americans. Dedicated to providing the world with a wide variety ... consumers focus on, one episode at a time. , In the latest installment ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... Bajos, November 26, 2015 Un ... de Bremachlorin para el cáncer avanzado.   ... la terapia fotodinámica de Bremachlorin para el cáncer avanzado. ... combina la inmunoterapia con la terapia fotodinámica de Bremachlorin ... Cancer Research . --> Clinical Cancer Research ...
(Date:11/26/2015)... 2015 --> ... combineert immunotherapie met Bremachlorin-photodynamische therapie voor de ... ) --> ... ) Uit een ... (LUMC) blijkt dat ...
(Date:11/26/2015)... 3D bioprinting market is expected ... new report by Grand View Research Inc. Rising prevalence of ... kidney transplantation is expected to boost the market growth, as ... transplantation. --> 3D bioprinting market is expected ... new report by Grand View Research Inc. Rising prevalence of ...
Breaking Medicine Technology: